Live Feeds
● LIVE Updated 30d ago · 24 sources tracked

Biogen makes up to $1B deal for secretive anti-inflammatory biotech

Biogen is buying San Diego-based RayThera to expand its immunology pipeline. The deal adds three preclinical anti-inflammatory assets. The total value of the acquisition is up to $1 billion.

RSS Source map (23)

What changed

The total potential value of the acquisition is now confirmed at $1 billion.

Live updates

  1. Biogen acquires RayThera in deal worth up to $1 billion

    Biogen is buying San Diego-based RayThera to expand its immunology pipeline. The deal adds three preclinical anti-inflammatory assets. The total value of the acquisition is up to $1 billion.

    What's confirmed:

    • Biogen agreed to acquire RayThera for up to $1 billion.
    • The acquisition adds three preclinical anti-inflammatory assets to Biogen's immunology pipeline.

    Still unconfirmed:

    • The assets acquired from RayThera are small-molecule anti-inflammatories.
    • Biogen is pivoting toward partnerships.
    confidence 100%

  2. Biogen to Acquire RayThera for Up to $1 Billion

    Biogen is acquiring San Diego-based RayThera to grow its immunology pipeline. The deal includes three preclinical anti-inflammatory assets. Payment consists of an upfront sum and milestones linked to regulatory and clinical success.

    What's confirmed:

    • Biogen is acquiring RayThera for up to $1 billion.
    • The acquisition adds three preclinical anti-inflammatory assets to Biogen's pipeline.
    • The deal involves an upfront payment and milestone payments based on clinical and regulatory success.
    confidence 100%

  3. Biogen Agrees to Acquire RayThera for Up to $1 Billion

    Biogen has reached an agreement to buy San Diego-based RayThera to expand its immunology pipeline. The deal provides Biogen with three preclinical small-molecule anti-inflammatory assets. A lead candidate is expected to enter Phase 1 clinical development in early Q3 2026.

    What's confirmed:

    • Biogen agreed to acquire RayThera for up to $1 billion.
    • The acquisition includes three preclinical anti-inflammatory programs.
    • RayThera is based in San Diego.
    • The lead candidate is slated for Phase 1 development in early Q3 2026.
    • The deal consists of an upfront cash payment and contingent milestone payments.
    • Completion of the transaction is expected in the third quarter of 2026.
    confidence 100%